ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019
Predictive Value of Positron Emission Tomography/Computed Tomography After ABVD-Based Chemotherapy in Early-Stage Hodgkin Lymphoma.
Abstract readLetterComment
In one paragraph
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
- Comment on
Authors and funding
9 authors at 1 institution in 1 country.
Carsten KobeCarsten Kobe, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Helen Goergen, Dipl-Math, Michael Fuchs, MD, and Horst Müller, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Christan Baues, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Andreas Engert, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Markus Dietlein, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; and Bastian von Tresckow, MD and Peter Borchmann, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Helen GoergenCarsten Kobe, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Helen Goergen, Dipl-Math, Michael Fuchs, MD, and Horst Müller, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Christan Baues, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Andreas Engert, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Markus Dietlein, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; and Bastian von Tresckow, MD and Peter Borchmann, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Michael FuchsCarsten Kobe, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Helen Goergen, Dipl-Math, Michael Fuchs, MD, and Horst Müller, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Christan Baues, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Andreas Engert, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Markus Dietlein, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; and Bastian von Tresckow, MD and Peter Borchmann, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Horst MüllerCarsten Kobe, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Helen Goergen, Dipl-Math, Michael Fuchs, MD, and Horst Müller, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Christan Baues, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Andreas Engert, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Markus Dietlein, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; and Bastian von Tresckow, MD and Peter Borchmann, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Christan BauesCarsten Kobe, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Helen Goergen, Dipl-Math, Michael Fuchs, MD, and Horst Müller, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Christan Baues, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Andreas Engert, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Markus Dietlein, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; and Bastian von Tresckow, MD and Peter Borchmann, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Andreas EngertCarsten Kobe, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Helen Goergen, Dipl-Math, Michael Fuchs, MD, and Horst Müller, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Christan Baues, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Andreas Engert, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Markus Dietlein, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; and Bastian von Tresckow, MD and Peter Borchmann, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Markus DietleinCarsten Kobe, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Helen Goergen, Dipl-Math, Michael Fuchs, MD, and Horst Müller, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Christan Baues, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Andreas Engert, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Markus Dietlein, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; and Bastian von Tresckow, MD and Peter Borchmann, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Bastian von TresckowCarsten Kobe, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Helen Goergen, Dipl-Math, Michael Fuchs, MD, and Horst Müller, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Christan Baues, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Andreas Engert, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Markus Dietlein, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; and Bastian von Tresckow, MD and Peter Borchmann, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Peter BorchmannCarsten Kobe, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Helen Goergen, Dipl-Math, Michael Fuchs, MD, and Horst Müller, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Christan Baues, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; Andreas Engert, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany; Markus Dietlein, MD, University Hospital of Cologne, University of Cologne, Cologne, Germany; and Bastian von Tresckow, MD and Peter Borchmann, MD, German Hodgkin Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
Düsseldorf University Hospital · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Hodgkin DiseaseAntineoplastic Combined Chemotherapy ProtocolsBleomycinDacarbazineDoxorubicinHumansPositron-Emission TomographyPrognosisRisk AssessmentUnited KingdomVinblastineBleomycinDacarbazineDoxorubicinVinblastine
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.